Technology
Health
Biotechnology
AVROBIO
$22.779876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$22.77
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.78 (3.52%) As of 10:33 AM EDT today
+$0.78 (3.52%) Today
Why Robinhood?
You can buy or sell AVROBIO and other stocks, options, ETFs, and crypto commission-free!
About AVRO
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. Read More These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.
CEO
Employees
49
Headquarters
Cambridge, Massachusetts
Founded
2015
Market Cap
526.75M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
984.07K
High Today
$23.30
Low Today
$21.96
Open Price
$22.10
Volume
233.88K
52 Week High
$53.70
52 Week Low
$11.85
Collections
Technology
Health
Biotechnology
Gene Therapies
Therapy
2018 IPO
US
North America
Price Paid on Robinhood
5% Higher
Right Now
52 Week Low
$11.85
Average Price Paid
$21.64
52 Week High
$53.70
Analyst Ratings
88%
of 8 ratings
Buy
88%
Hold
13%
Sell
0%
AVRO Earnings
-$2.98
-$2.15
-$1.32
-$0.49
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 8, Pre-Market